NDC 50419-391 – Vitrakvi
Larotrectinib 100 mg/1 · Capsule · Oral
Product NDC50419-391
Product details
- Brand name
- Vitrakvi
- Generic name
- Larotrectinib
- Labeler
- Bayer HealthCare Pharmaceuticals Inc.
- Dosage form
- Capsule
- Route
- Oral
- Marketing category
- NDA · NDA210861
- Marketed since
- July 26, 2019
- Listing expires
- December 31, 2027
- Pharmacologic class
- Kinase Inhibitor
Active ingredients
- Larotrectinib 100 mg/1
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 50419-391-01 | 60 CAPSULE in 1 BOTTLE (50419-391-01) | Jul 26, 2019 |
Recalls mentioning this NDC
- D-0145-2024 Dec 6, 2023 · Class I
Microbial Contamination of Non-Sterile Products: microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing
Other Vitrakvi products
- 50419-390 Larotrectinib 25 mg/1 · Capsule · Bayer HealthCare Pharmaceuticals Inc.
- 50419-392 Larotrectinib 20 mg/mL · Solution, Concentrate · Bayer HealthCare Pharmaceuticals Inc.
- 50419-393 Larotrectinib 20 mg/mL · Solution, Concentrate · Bayer HealthCare Pharmaceuticals Inc.
- 71777-390 Larotrectinib 25 mg/1 · Capsule · Loxo Oncology, Inc.
- 71777-391 Larotrectinib 100 mg/1 · Capsule · Loxo Oncology, Inc.
- 71777-392 Larotrectinib 20 mg/mL · Solution · Loxo Oncology, Inc.